Cohance Lifesciences Stock Price Analysis and Quick Research Report. Is Cohance Lifesciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Cohance Lifesciences. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Cohance Lifesciences has a PE ratio of 149.613145678285 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Cohance Lifesciences has ROA of 11.3168% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Cohance Lifesciences has a Current ratio of 3.3193.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Cohance Lifesciences has a ROE of 12.5645%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Cohance Lifesciences has a Debt to Equity ratio of 0.0305 which means that the company has low proportion of debt in its capital.

• Sales growth: Cohance Lifesciences has reported revenue growth of 4.0101% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Cohance Lifesciences for the current financial year is 33.1565326334464%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Cohance Lifesciences is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Cohance Lifesciences is Rs 6.7855. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Cohance Lifesciences in Ticker for free. Also, one can get the intrinsic value of Cohance Lifesciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Cohance Lifesciences FAQs

Q1. What is Cohance Lifesciences share price today?
Ans: The current share price of Cohance Lifesciences is Rs 1015.2.

Q2. What is the market capitalisation of Cohance Lifesciences?
Ans: Cohance Lifesciences has a market capitalisation of Rs 38838.2160528 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Cohance Lifesciences?
Ans: The PE ratio of Cohance Lifesciences is 149.613145678285 and the P/B ratio of Cohance Lifesciences is 16.4288326660604, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Cohance Lifesciences share?
Ans: The 52-week high share price of Cohance Lifesciences is Rs 1360, and the 52-week low share price of Cohance Lifesciences is Rs 856.3.

Q5. Does Cohance Lifesciences pay dividends?
Ans: Currently, Cohance Lifesciences does not pay dividends. Dividend yield of Cohance Lifesciences is around 0%.

Q6. What are the face value and book value of Cohance Lifesciences shares?
Ans: The face value of Cohance Lifesciences shares is Rs 1, while the book value per share of Cohance Lifesciences is around Rs 61.7938. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Cohance Lifesciences?
Ans: Cohance Lifesciences has a total debt of Rs 70 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Cohance Lifesciences?
Ans: The ROE of Cohance Lifesciences is 12.5645% and ROCE of Cohance Lifesciences is 16.1416%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Cohance Lifesciences a good buy for the long term?
Ans: The Cohance Lifesciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Cohance Lifesciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Cohance Lifesciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Cohance Lifesciences’s financials?
Ans: You can review Cohance Lifesciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.